{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T21:23:31Z","timestamp":1771104211808,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mucopolysaccharidosis type I (MPS I) is traditionally divided into three phenotypes: the severe Hurler (MPS I-H) phenotype, the intermediate Hurler-Scheie (MPS I-H\/S) phenotype and the attenuated Scheie (MPS I-S) phenotype. However, there are no clear criteria for delineating the different phenotypes. Because decisions about optimal treatment (enzyme replacement therapy or hematopoietic stem cell transplantation) need to be made quickly and depend on the presumed phenotype, an assessment of phenotypic severity should be performed soon after diagnosis. Therefore, a numerical severity scale for classifying different MPS I phenotypes at diagnosis based on clinical signs and symptoms was developed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A consensus procedure based on a combined modified Delphi method and a nominal group technique was undertaken. It consisted of two written rounds and a face-to-face meeting. Sixteen MPS I experts participated in the process. The main goal was to identify the most important indicators of phenotypic severity and include these in a numerical severity scale. The correlation between the median subjective expert MPS I rating and the scores derived from this severity scale was used as an indicator of validity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Full consensus was reached on six key clinical items for assessing severity: age of onset of signs and symptoms, developmental delay, joint stiffness\/arthropathy\/contractures, kyphosis, cardiomyopathy and large head\/frontal bossing. Due to the remarkably large variability in the expert MPS I assessments, however, a reliable numerical scale could not be constructed. Because of this variability, such a scale would always result in patients whose calculated severity score differed unacceptably from the median expert severity score, which was considered to be the 'gold standard'.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although consensus was reached on the six key items for assessing phenotypic severity in MPS I, expert opinion on phenotypic severity at diagnosis proved to be highly variable. This subjectivity emphasizes the need for validated biomarkers and improved genotype-phenotype correlations that can be incorporated into phenotypic severity assessments at diagnosis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1750-1172-7-22","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T10:27:36Z","timestamp":1335176856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure"],"prefix":"10.1186","volume":"7","author":[{"given":"Minke H","family":"de Ru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quirine GA","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna H","family":"van der Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf A","family":"Bodamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorne A","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla E","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuan-Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Ver\u00f3nica Mu\u00f1oz","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory M","family":"Pastores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian A","family":"Raiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen P","family":"Treacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tylki-Szymanska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Edmond Wraith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Zeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits A","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,23]]},"reference":[{"key":"377_CR1","volume-title":"In The Online Metabolic and Molecular Bases of Inherited Disease","author":"EF Neufeld","year":"2007","unstructured":"Neufeld EF, Muenzer J: The mucopolysaccharidoses. In The Online Metabolic and Molecular Bases of Inherited Disease chapter 136 edition. Edited by: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A. New York: McGraw-Hill; 2007.","edition":"chapter 136"},{"key":"377_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.GIM.0000078027.83236.49","volume":"5","author":"NJ Terlato","year":"2003","unstructured":"Terlato NJ, Cox GF: Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med. 2003, 5: 286-294. 10.1097\/01.GIM.0000078027.83236.49.","journal-title":"Genet Med"},{"key":"377_CR3","doi-asserted-by":"publisher","first-page":"E2189","DOI":"10.1002\/humu.21479","volume":"32","author":"F Bertola","year":"2011","unstructured":"Bertola F, Filocamo M, Casati G, Mort M, Rosano C, Tylki-Szymanska A, T\u00fcys\u00fcz B, Gabrielli O, Grossi S, Scarpa M, Parenti G, Antuzzi D, Dalmau J, Rocco MD, Vici CD, Okur I, Rosell J, Rovelli A, Furlan F, Rigoldi M, Biondi A, Cooper DN, Parini R: IDUA mutational profiling of a cohort of 102 European patients with Mucopolysaccharidosis type I: identification and characterization of 35 novel \u03b1-L-iduronidase (IDUA) alleles. Hum Mutat. 2011, 32: E2189-E2210. 10.1002\/humu.21479.","journal-title":"Hum Mutat"},{"key":"377_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/adc.2007.135772","volume":"94","author":"AM Murphy","year":"2009","unstructured":"Murphy AM, Lambert D, Treacy EP, O'Meara A, Lynch SA: Incidence and prevalence of mucopolysaccharidosis type 1 in the Irish republic. Arch Dis Child. 2009, 94: 52-54. 10.1136\/adc.2007.135772.","journal-title":"Arch Dis Child"},{"key":"377_CR5","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/ajmg.a.32781","volume":"149A","author":"HY Lin","year":"2009","unstructured":"Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, Chao MC, Chiu PC, Lin SJ, Tsai LP, Hwu WL, Lin JL: Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A. 2009, 149A: 960-964. 10.1002\/ajmg.a.32781.","journal-title":"Am J Med Genet A"},{"key":"377_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1542\/peds.2008-0416","volume":"123","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Wraith JE, Clarke LA: Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009, 123: 19-29. 10.1542\/peds.2008-0416.","journal-title":"Pediatrics"},{"key":"377_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ymgme.2007.01.011","volume":"91","author":"GM Pastores","year":"2007","unstructured":"Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, Muenzer J, Norato DY, Shapiro E, Thomas J, Viskochil D, Wraith JE: The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type i. Mol Genet Metab. 2007, 91: 37-47. 10.1016\/j.ymgme.2007.01.011.","journal-title":"Mol Genet Metab"},{"key":"377_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/01.bor.0000147283.40529.13","volume":"17","author":"GM Pastores","year":"2005","unstructured":"Pastores GM, Meere PA: Musculoskeletal complications associated with lysosomal storage disorders: gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol. 2005, 17: 70-78. 10.1097\/01.bor.0000147283.40529.13.","journal-title":"Curr Opin Rheumatol"},{"key":"377_CR9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1080\/08035250510031584","volume":"94","author":"S Vijay","year":"2005","unstructured":"Vijay S, Wraith JE: Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005, 94: 872-877. 10.1080\/08035250510031584.","journal-title":"Acta Paediatr"},{"key":"377_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pcl.2009.11.004","volume":"57","author":"JJ Boelens","year":"2010","unstructured":"Boelens JJ, Prasad VK, Tolar J, Wynn RF, Peters C: Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am. 2010, 57: 123-145. 10.1016\/j.pcl.2009.11.004.","journal-title":"Pediatr Clin North Am"},{"key":"377_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbmt.2008.01.009","volume":"14","author":"M Aldenhoven","year":"2008","unstructured":"Aldenhoven M, Boelens JJ, de Koning TJ: The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant. 2008, 14: 485-498. 10.1016\/j.bbmt.2008.01.009.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"377_CR12","doi-asserted-by":"publisher","first-page":"55.","DOI":"10.1186\/1750-1172-6-55","volume":"10","author":"MH de Ru","year":"2011","unstructured":"de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, Mengel E, Offringa M, O'Meara A, Parini R, Rovelli A, Sykora KW, Valayannopoulos V, Vellodi A, Wynn RF, Wijburg FA: Enzyme Replacement Therapy and\/or Hematopoietic Stem Cell Transplantation at diagnosis in patients with Mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011, 10 (6): 55..","journal-title":"Orphanet J Rare Dis"},{"key":"377_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Philips J, Doreshow R, Walot I, Hoft R, Neufeld EF: Enzyme replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001, 344: 182-188. 10.1056\/NEJM200101183440304.","journal-title":"N Engl J Med"},{"key":"377_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF: Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alfa-l-iduronidase (laronidase). J Pediatr. 2004, 144: 581-588. 10.1016\/j.jpeds.2004.01.046.","journal-title":"J Pediatr"},{"key":"377_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, Okazaki S, Huff K, Cox GF, Swiedler SJ, Kakkis ED: A follow-op study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007, 90: 171-180. 10.1016\/j.ymgme.2006.08.007.","journal-title":"Mol Genet Metab"},{"key":"377_CR16","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, Kakkis ED, Guffon N: Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alfa-l-iduronidase (laronidase). Paediatrics. 2007, 120: e37-e46. 10.1542\/peds.2006-2156.","journal-title":"Paediatrics"},{"key":"377_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Cox GF: Long-term efficacy and safety of laronidase in the treatment of Mucopolysaccharidosis I. Pediatrics. 2009, 123: 229-240. 10.1542\/peds.2007-3847.","journal-title":"Pediatrics"},{"key":"377_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/bmme.1996.0044","volume":"58","author":"ED Kakkis","year":"1996","unstructured":"Kakkis ED, McEntee MF, Schmidtchen A, Neufeld EF, Ward DA, Gompf RE, Kania S, Bedolla C, Chien SL, Shull RM: Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med. 1996, 58: 156-167. 10.1006\/bmme.1996.0044.","journal-title":"Biochem Mol Med"},{"key":"377_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbmt.2009.01.020","volume":"15","author":"JJ Boelens","year":"2009","unstructured":"Boelens JJ, Rocha V, Aldenhoven M, Wynn R, O'Meara A, Michel G, Ionescu I, Parikh S, Prasad VK, Szabolcs P, Escolar M, Gluckman E, Cavazzana-Calvo M, Kurtzberg J: EUROCORD, inborn error working party of ebmt and duke university: risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant. 2009, 15: 618-625. 10.1016\/j.bbmt.2009.01.020.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 2","key":"377_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.bbmt.2009.12.091","volume":"16","author":"JJ Boelens","year":"2010","unstructured":"Boelens JJ, Aldenhoven M, Purtill D, Eapen M, DeForr T, Wynn R, Cavazanna-Calvo M, Tolar J, Prasad VK, Escolar M, Gluckman E, Orchard P, Veys P, Kurtzberg J, Rocha V: Outcomes of transplantation using a various cell source in children with Hurlers syndrome after myelo-ablative conditioning. An Eurocord-EBMT-CIBMTR collaborative study. Biol Blood Marrow Transplant. 2010, 16 (Suppl 2): 180-181.","journal-title":"Biol Blood Marrow Transplant"},{"key":"377_CR21","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1542\/peds.2009-1728","volume":"125","author":"O Gabrielli","year":"2010","unstructured":"Gabrielli O, Clarke LA, Bruni S, Coppa GV: Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2010, 125: e183-e187. 10.1542\/peds.2009-1728.","journal-title":"Pediatrics"},{"key":"377_CR22","doi-asserted-by":"publisher","first-page":"a744","DOI":"10.1136\/bmj.a744","volume":"337","author":"R Jaeschke","year":"2008","unstructured":"Jaeschke R, Guyatt GH, Dellinger P, Sch\u00fcnemann H, Levy MM, Kunz R, Norris S, Bion J: GRADE Working Group: Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008, 337: a744-10.1136\/bmj.a744.","journal-title":"BMJ"},{"key":"377_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1469-8749.1997.tb07414.x","volume":"39","author":"R Palisano","year":"1997","unstructured":"Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B: Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997, 39: 214-223.","journal-title":"Dev Med Child Neurol"},{"key":"377_CR24","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198528470.001.0001","volume-title":"Health measurement scales; a practical guide to their development and use","author":"DL Streiner","year":"2003","unstructured":"Streiner DL, Norman GR: Health measurement scales; a practical guide to their development and use. 2003, Oxford: Oxford University Press"},{"key":"377_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP: Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996, 1: 30-46.","journal-title":"Psychol Methods"},{"key":"377_CR26","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1373\/clinchem.2008.115410","volume":"54","author":"S Blanchard","year":"2008","unstructured":"Blanchard S, Sadilek M, Scott CR, Turecek F, Gelb MH: Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem. 2008, 54: 2067-2070. 10.1373\/clinchem.2008.115410.","journal-title":"Clin Chem"},{"key":"377_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1373\/clinchem.2004.047167","volume":"51","author":"D Wang","year":"2005","unstructured":"Wang D, Eadala B, Sadilek M, Chamoles NA, Turecek F, Scott CR, Gelb MH: Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem. 2005, 51: 898-900. 10.1373\/clinchem.2004.047167.","journal-title":"Clin Chem"},{"key":"377_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ymgme.2006.02.013","volume":"88","author":"PJ Meikle","year":"2006","unstructured":"Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, Fietz MJ, Simonsen H, Fuller M, Brooks DA, Hopwood JJ: Newborn screening for lysosomal storage disorders. Mol Genet Metab. 2006, 88: 307-314. 10.1016\/j.ymgme.2006.02.013.","journal-title":"Mol Genet Metab"},{"key":"377_CR29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2008.05.001","volume":"94","author":"DR Randall","year":"2008","unstructured":"Randall DR, Colobong KE, Hemmelgarn H, Sinclair GB, Hetty E, Thomas A, Bodamer OA, Volkmar B, Fernhoff PM, Casey R, Chan AK, Mitchell G, Stockler S, Melancon S, Rupar T, Clarke LA: Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol Genet Metab. 2008, 94: 456-461. 10.1016\/j.ymgme.2008.05.001.","journal-title":"Mol Genet Metab"},{"key":"377_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10545-010-9254-8","volume":"34","author":"KJ Langford-Smith","year":"2010","unstructured":"Langford-Smith KJ, Mercer J, Petty J, Tylee K, Church H, Roberts J, Moss G, Jones S, Wynn R, Wraith JE, Bigger BW: Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases. J Inherit Metab Dis. 2010, 34: 499-508.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-7-22.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T18:22:08Z","timestamp":1713896528000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/1750-1172-7-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1186\/1750-1172-7-22","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,23]]},"assertion":[{"value":"27 November 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"22"}}